The FDA has approved oral semaglutide (Wegovy) for chronic weight management, marking the first GLP-1 pill available for obesity treatment in the United States. This breakthrough eliminates the need for weekly injections that have been a barrier for many patients considering weight management therapy.
The Phase III OASIS 4 trial